QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
January 04 2008 - 4:35PM
PR Newswire (US)
NEW YORK, Jan. 4 /PRNewswire-FirstCall/ -- QED International
Associates, Inc, administrator for the HealthShares(TM) Indexes, a
series of 20 underlying indexes for the HealthShares
Exchange-Traded Funds, today announced that effective at the
opening of trading on Monday January 7, 2008, ArQule, Inc.
(NASDAQ:ARQL) will replace Coley Pharmaceutical, Inc. (NASDAQ:COLY)
in the HealthShares(TM) Emerging Cancer Index. Coley Pharmaceutical
is being acquired by Pfizer, Inc. (NYSE:PFE), with 92% of the
outstanding shares of COLY tendered under an offer expired December
28, 2007. Companies included in the HealthShares(TM) Emerging
Cancer Index are engaged in the research, clinical development
and/or commercialization of therapeutic agents for the treatment of
a wide variety of cancers. They generally include those with some
level of revenues, or those on the verge of revenues with
significant but focused research and development programs. About
QED International Associates QEDI International, based in New York,
is a leading financial industry consulting firm specializing in
quantitative modeling and the design, development and maintenance
of indexes and Exchange Traded Funds. For more information, visit
the company's website at http://www.qedinternational.com/.
DATASOURCE: QED International Associates, Inc CONTACT: Ed Matluck,
CEO, or Michael Carty, Senior Advisor, Senior Vice President, both
for QED International, +1-212-953-4058, Web site:
http://www.qedinternational.com/
Copyright
Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Historical Stock Chart
From May 2024 to Jun 2024
Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Coley Pharmaceutical Grp. (MM) (NASDAQ): 0 recent articles
More Coley Pharmaceutical Grp. (MM) News Articles